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Herpes simplex encephalitis (HSE) is a serious disease with 10-20% mortality and high rate of neuropsychiatric sequelae.
This study is a long-term, nationwide study in a single country, Iceland. Clinical data were obtained from patient records
and from DNA PCR and antibody assays of CSF. Diagnosis of HSE was classified as definite, possible or rejected based
on symptoms, as well as virological, laboratory and brain imaging criteria. A total of 30 definite cases of HSE were
identified during the 25 year period 1987-2011 corresponding to incidence of 4.3 cases/106 inhabitants/year. Males
were 57% of all patients, median age 50 years (range, 0-85). Fever (97%), cognitive deficits (79%), impaired consciousness
(79% with GCS < 13), headache (55%) and seizures (55%) were the most common symptoms. Brain lesions were found
in 24 patients (80%) by MRI or CT. All patients received intravenous acyclovir for a mean duration of 20 days. Three
patients (10%) died within one year and 21/28 pts (75%) had a Karnofsky performance score of <70% with memory loss
(59%), dysphasia (44%), frontal symptoms (44%) and seizures (30%) as the most frequent sequelae. Mean delay from
onset of symptoms to treatment was 6 days; this was associated with adverse outcome. In conclusion, the incidence of
`HSE is higher than recently reported in a national registry study from Sweden. Despite advances in rapid diagnosis and
availability of treatment of HSE, approximately three of every four patients die or are left with serious neurological
impairment.
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Herpes simplex virus (HSV) causes various infections in
humans, including encephalitis. HSV is the most common
cause of non-epidemic encephalitis worldwide (Granerod
et al. 2010; Banatvala 2011). Herpes simplex encephalitis
(HSE) is a rare disease. The majority of cases (>90%) are
due to HSV type 1 (HSV-1) and HSV type 2 (HSV-2) is
the main cause of neonatal HSV infection (Aurelius et al.
1993). In a recent Swedish nationwide register-based study
the incidence of confirmed HSE was 2.2 cases per million
population per year (Hjalmarsson et al. 2007). The mortal-
ity of patients with HSE is 70% in the absence of treatment
and most survivors have severe neurological impairment
(Whitley et al. 1977). In the past 3 decades, two major im-
provements have improved mortality and morbidity of pa-
tients with HSE. In the mid-1980s two large randomized
trials showed that treatment with intravenous acyclovir* Correspondence: siggudm@landspitali.is
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in any medium, provided the original work is p(ACV) reduced the mortality rate and decreased morbidity
(Whitley et al. 1986; Skoldenberg et al. 1984). The establish-
ment of polymerase chain reaction (PCR)–based diagnosis
of HSV in cerebrospinal fluid (CSF) has facilitated faster
and more reliable diagnosis of the disease, replacing the
previous gold standard of brain biopsy (Aurelius et al. 1991;
Lakeman and Whitley 1995; Scoular et al. 2002; Cinque
et al. 1996). Furthermore, diagnostic accuracy has improved
markedly with advances in neuroradiological imaging, in
particular magnetic resonance imaging (MRI) (Domingues
et al. 1998). Despite these advances the mortality is 15–20%
and prevalence of neurological sequelae may range from
20–50 (Whitley et al. 1986; Raschilas et al. 2002).
Within the past decade several studies have improved
our understanding of the epidemiology and etiology of
encephalitis and the relative incidence of HSE as a cause
of the acute encephalitis syndrome (Glaser et al. 2003;
Barbadoro et al. 2012). In addition, the Swedish register-
based study mentioned above was the first published na-
tionwide study on HSE proper with regard to incidence,
mortality and patients’ outcome. The objective of our
study was to describe the epidemiology of HSE in ais an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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to analyze clinical parameters such as main symptoms,
diagnostic studies, treatment and outcomes directly from
patient records.Methods
Setting
Iceland has a national health care system, with compre-
hensive hospital registries. The population in 1987 was
245.962 and 319.014 in 2011 (Statistics Iceland). There
are two referral hospitals in the country, the Landspitali
University Hospital in Reykjavik and the Akureyri Hos-
pital in Northern Iceland.
All cases of serious illnesses suggestive of encephalitis
are referred to these two hospitals for diagnosis and
management.Patients
All potential cases of HSE in Iceland from January 1987
through December 2011 were reviewed. Patients were
identified by discharge diagnoses (according to Inter-
national Classification of Diseases, Ninth and Tenth Revi-
sion, ICD-9 and ICD-10; ICD9 054.3, 323.4; ICD10 B00.4,
G05.1, A86). In addition, all cases diagnosed with a posi-
tive HSV DNA PCR or by detection of intrathecal HSV
specific antibody production in CSF were reviewed. Ana-
lysis of intrathecal antibody index (IAI) was performed by
calculating the ratio of HSV antibodies in CSF relative to
HSV antibodies in serum, as well as measuring antibodies
for measles virus for comparison to rule out breach in the
blood–brain barrier (Jacobi et al. 2007). The PCR assay
for HSV was introduced in 1994 but until January 1998 it
did not allow for typing into types 1 and 2. Separation into
types was also not possible with the IAI assay performed
during the whole study period.
By this approach 91 cases were identified. Their charts
were reviewed retrospectively and clinical parameters reg-
istered, including symptoms, lesions identified on com-
puted tomography (CT), magnetic resonance imaging
(MRI) and electroencephalography (EEG), treatment and
sequelae. State of consciousness was determined by the
Glasgow coma scale (GCS) (Teasdale and Jennett 1974)
and outcome was assessed using the Karnofsky per-
formance scale measuring functional impairment (KPS)
(Karnofsky et al. 1948). In both instances the patients
were retrospectively scored based on information in the
patient record at discharge, most often from the re-
habilitation unit or from last documentation of contact
in the record.
The study was approved by the National Bioethics
Committee (ref. no. VSNb2011110005/03.7) and the Ice-
landic Data Protection Agency (ref. no. 201111138ÞS/-).Criteria
The diagnosis of HSE was established by using criteria
developed by the authors to assess whether a patient had
definite or possible diagnosis. Those who did not fulfill
these criteria were excluded from the study. The follow-
ing criteria were used: Major criteria were defined as 1)
positive PCR for HSV or elevated IAI in CSF, 2) positive
brain biopsy and 3) positive imaging study (CT or MRI)
suspicious for HSE. Minor criteria were defined as 1)
seizures, 2) cognitive deficits, 3) fever, 4) elevated white
or red blood cells in CSF and 5) positive EEG findings.
Definite diagnosis of HSE required the patient to have
two major criteria, one major and three minor criteria
or all of the five minor criteria and no alternative diag-
noses. Possible diagnosis of HSE was defined as one
major and two minor criteria or 3–4 minor criteria and
no likely differential diagnoses.
These methods led to finding of 28 definite cases and
three possible cases from 1987 through 2011. The three
possible cases all occurred before 1993. Their CSF samples
were retrieved from storage and PCR for HSV-1 per-
formed, yielding two positives. Thus, the final cohort of
patients consisted of 30 definite cases of HSE (Figure 1).
Statistics
The incidence of HSE was calculated based on population
data from Statistics Iceland (Statistics Iceland). The statis-
tical software packages SAS (SAS Institute Inc., Cary,
North Carolina, USA, 2010) and R (Prolink Corporation,
Naples, Florida, USA, 2009) were used to calculate confi-
dence intervals, perform logistic regression, chi square test
and Fisher test as appropriate. Two-tailed p values of <0.05
were considered to indicate statistical significance.
Results
Incidence
Out of 91 patient records reviewed, a total of 30 patients
were identified as having a definite diagnosis of HSE dur-
ing the 25-year period 1987- 2011 (Figure 1). This corre-
sponds to an incidence of 4.3 cases of HSE per million
population per year (95% CI, 2.9–6.1 cases per million
population per year). Figure 2 shows incidence over three
8 and 9 year periods. There was neither significant vari-
ation in incidence between those periods (p = 0.78) nor
trend over time (p = 0.51). No significant difference in in-
cidence between seasons was noted (p > 0.05).
Virological diagnosis
HSV PCR assay was performed on the CSF of 25 of the
patients in the cohort, 22 had positive PCR and 3 nega-
tive. During the study period a total of 48 patients had a
positive PCR of CSF. The other 26 patients with positive
HSV PCR who did not fulfill the criteria for HSE all had
HSV meningitis (Figure 1). CSF PCR was not done on 5
Figure 1 Flow chart showing the study’s population.
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Thus, 8 patients in the cohort either had a negative PCR
or it was not performed. Five of those 8 patients had a
positive IAI, but 3 patients were diagnosed based on
other criteria, two had one major and three minor cri-
teria, and one patient had five minor criteria.Age and gender
Of the 30 patients, 17 (57%) were males. Patients’ ages
ranged from 0 to 85 years with a mean of 47 years (SD,
24 years) and median of 50 years (interquartile range
(IQR), 34–68 years). The median age was 46 years in fe-
male patients (IQR, 22–72 years) and 51 years in male
patients (IQR, 44–66 years). Age-specific incidence for
the entre cohort is shown in Figure 3.Figure 2 Changes in incidence in the period 1987–2011, p > 0.05.Clinical features
Information about clinical features of all the patients
was obtained. Fever was the most common feature
(97%) and the average temperature was 38.6°C (STD,
0.8°C). Seventeen patients (57%) had seizures and 23 pa-
tients (79%) had one or more symptoms of cognitive im-
pairment, of which confusion was the most common
(76%). Twenty-four patients had maximum or medium
alteration of consciousness over the course of the illness,
i.e. a score of less than 12 on the GCS, and of those, 13
patients (43%) had GCS score of less than 8.Cerebrospinal fluid
All but one patient (97%) had an elevated white blood
cell count (>3 × 106/L) in the CSF with a median of 74 ×
Figure 3 Age distribution of patients.
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had more than 100 × 106/L WBC. All but five patients
had an increased amount of red blood cells (>1 × 106/L)
in CSF and five patients (17%) had more than 100 × 106/
L RBC in the CSF. Seventeen (57%) patients had in-
creased level of protein (>600 mg/L) in the CSF with an
average amount of 841 mg/L (STD, 521 mg/L).Imaging
Thirteen patients (43%) had only CT scans whilst the
remaining 17 patients (57%) had an MRI. Diagnostic im-
aging (MRI and CT) showed lesions in 24 cases (80%),
of which all but one patient (97%) had lesions in the
temporal lobe (Table 1).Table 1 Number and ratio of patients who had CT or MRI




Total number of patients receiving imaging
study
30* 100%
Normal CT or MRI 6** 20%
Abnormal CT or MRI 24*** 80%
Temporal lobe**** 23 96%
Other than temporal lobe***** 1 4%
Lesion in one hemisphere 19 79%
Lesions in both hemispheres 5 21%
*17 patients had MRI and 13 patients only CT.
**1 patient with MRI and 5 patients with only CT.
***16 patients with MRI and 8 patients with only CT.
****Lesions in temporal lobe with or without lesions in other sites of the brain.
*****One patient had no lesions in the temporal lobes, only lesions confined
to the occipital lobe and corpus callosum.Treatment
All patients received intravenous ACV for an average of
20 days (SD, 7 days). Information about morbidity and
impairment after HSE was available for 28 patients
(93%). Average time delay from the onset of symptoms
until treatment with intravenous ACV was initiated was
six days (SD, 6 days) and median four days (IQR, 3–8
days). This information was available for 28 patients.
The association between duration of symptoms until
treatment initiation and functional status after the illness
is shown in Figure 4. The OR of being in KPS category 2
and 3 vs. KPS category 1 for each day of delay is 0.76
(95% CI 0.55–0.94, p = 0.04). The mean delay from ad-
mission to initiation of treatment was 2 days (SD, 5 days)
and median 1 day (IQR, 0–2 days). Four patients re-
ceived steroids.Outcome
Three (10%) patients died within one year (95% CI, 2–
27%), all female. Seven of a total of 28 patients (25%) for
which information on performance outcome was available
had 80–100% ability to carry out activities of daily living
based on the KPS scale, 14 patients (50%) had 50–70%
ability and seven patients (25%, including the four who
died) had a KPS of 0–40%. Thus, 75% of the patients either
died or were left with serious sequelae. Of patients diag-
nosed during the first half (1987–1999) and the second half
(2000–2010), respectively, 83% and 71%, respectively, were
left with a KPS score of 70% or less (p =NS). Information
on specific sequelae was available for 27 patients, of those
a total of 23 (85%) had some sequelae, one or more, as
shown in Table 2. Steroid therapy (4 patients) did not influ-
ence outcome.
Figure 4 Distribution of delay (days) in treatment with intravenous ACV from the onset of symptoms (y-axis) compared to prognosis
after HSE (x-axis). The OR of being in Karnofsky performance scale (KPS) category 2 and 3 vs. KPS category 1 for each day of delay is 0.76 (95%
CI 0.55–0.94p = 0.04). Black dots indicate patients who died within a year from admission. *1 = 0–40% performance. 2 = 50–70% performance.
3 = 80–100% performance.
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In this long-term, population-based study the yearly inci-
dence of HSE was 4.1 cases/1.000.000 inhabitants. If the
single neonatal HSV-2 case is omitted, the incidence of
HSV-1 encephalitis was 4.1 cases/1.000.000 inhabitants.
This is considerably higher than the incidence of 2.2 re-
cently reported from Sweden for the years 1990–2001
(Hjalmarsson et al. 2007). This discordance could reflect a
true difference between the two countries, but the method
of case acquisition is also a potential explanation. The
Swedish study was based on ICD coded diagnoses for
HSE in the Swedish National Inpatient Register that has
covered all Swedish hospitals since 1987. Hospital-based
inpatient registries are also available in Icelandic hospitals,
but only 17 of a total of 29 patients (59%) with HSE in the
current study would have been identified by the registry
diagnoses for HSE alone. The remaining 12 cases were
identified from other ICD codes, but mainly from registry
of results of PCR testing and/or intrathecal antibodyTable 2 Morbidity after HSE
Sequelae Number Ratio
Memory loss 16 59%
Dysphasia 12 44%
Frontal symptoms 12 44%
Seizures 8 30%
Deep venous thrombosis 1 4%
Number of patients is shown with each impairment and the ratio of total
number of patients, (n = 27).production in CSF at the only virology laboratory in the
country. Cases of HSE in the Swedish study that were not
typed as HSV-1 or 2 were not included in the analysis, but
if they had been included the yearly incidence would have
been 2.5/1.000.000 inhabitants (Hjalmarsson et al. 2007).
In the current study, we made an attempt to apply a set
of rigorous criteria for inclusion, taking into account the
fact that in clinical practice the diagnostic approaches to
this disease may be different, especially given the long study
period. The diagnostic criteria developed by the authors
have a corollary in criteria employed for other diseases,
e.g. the modified Duke criteria for bacterial endocardi-
tis,(Li et al. 2000). Thus, patients without firm viro-
logical diagnosis were included in the study cohort
according to the diagnostic criteria, akin to patients
with culture negative endocarditis.
If the inclusion criteria used by Hjalmarsson et al. are
applied to the current study population, the annual inci-
dence in Iceland for 1999–2011 is 2.8/1.000.000, which is
within the confidence limits of the Swedish study. A re-
cent hospital-based registry from Italy 1999–2005 showed
that an annual HSE incidence of 3.9/million inhabitants),
very similar to the results in the current study (Barbadoro
et al. 2012). Thus, although it is well known that the inci-
dence of certain infectious diseases differ significantly by
geography, it is very likely that the true incidence of HSE
in both countries is very similar, but the methodology in
the current study was less restrictive.
Three of 24 patients had negative PCR results. One of
them presented outside the country, where facilities for
PCR were not available. Three weeks after onset of
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the PCR was negative, as it may be 10–14 days after on-
set of symptoms (Puchhammer-Stockl et al. 2001). The
diagnosis was made based on intrathecal antibody index
(IAI). The other two patients were included based on
other clinical or laboratory criteria. It is well known that
patients with HSE may have an initially negative PCR
and therefore the test should be repeated in patients in
whom the clinical suspicion is high (Weil et al. 2002).
IAI was determined in seven patients, with a signifi-
cant increase demonstrated for five. The remaining two
patients both had a positive PCR for HSV. Thus, the IAI
may have been tested too early in the course of the ill-
ness or it may be less sensitive than PCR.
Determinations of HSV types by PCR were begun at
our facilities in 1998, and prior to that, types were not
determined by antibody assays. Nevertheless, we in-
cluded non-typed HSV in the study (Aurelius et al.
1993). This approach is justified given the fact that be-
yond the neonatal period, HSE is almost entirely caused
by HSV-1 as demonstrated by Raschilas et al. (2002).
Fever was an almost universal symptom in our patients,
and cognitive dysfunction, convulsions and headache were
furthermore very common, as reported by others (Raschilas
et al. 2002; Whitley et al. 1982). Interestingly, in the pro-
spective study by Granerod and colleagues, fever was
present on admission in only 50% of the HSE patients
(Granerod et al. 2010). Forty-one percent of patients in our
study were found to have markedly impaired consciousness
(GCS score of <8) sometime in the course of illness as
compared with only 10% of the patients in the study by
Raschilas et al. (2002). However, the score in that study was
determined on admission. We report on the other hand the
lowest score during the course of the illness. In addition,
the score in our study was determined in many cases retro-
spectively based on descriptions in the patient record,
which certainly could bias our findings.
All but five patients had red blood cells in the CSF, as
reported by others (Raschilas et al. 2002; McGrath et al.
1997). However, only 55% of our patients had increased
protein level in the CSF, lower than reported by others
(Raschilas et al. 2002; Whitley et al. 1982). One-fifth of
our patients had normal imaging studies of the brain,
but not everyone underwent MRI, which is a more sensi-
tive diagnostic method than CT scan, especially for de-
tecting early changes (Schroth et al. 1987). The lesions
that were found were mostly in the temporal lobe, unilat-
eral in 78% and bilateral in 22%, in concordance with previ-
ous reports (Raschilas et al. 2002). In one patient the lesion
was in the occipital lobe resulting in significant visual loss.
All our patients received acyclovir, for mean duration
of 20 days. The mean delay from onset of symptoms and
initiation of treatment was 6 days and the delay from
hospital admission until treatment was 2 days, similar tothe delays reported by Raschilas et al. (2002). Further-
more, a significant association between duration of treat-
ment delay and adverse outcome was demonstrated as
reported previously by others (Raschilas et al. 2002;
McGrath et al. 1997).
Three patients died within one year from admission, or
10% which is concordant with other studies (Granerod
et al. 2010; Hjalmarsson et al. 2007; Raschilas et al. 2002).
Approximately 70% of the surviving patients were left with
disability following their illness, including memory loss,
frontal symptoms, dysphasia and seizure disorder, in ac-
cordance with previous reports (Granerod et al. 2010;
Hjalmarsson et al. 2007; McGrath et al. 1997; Stahl et al.
2012). Of interest is the recent study by Mailles et al.
where only 42% of patients with HSE had a long term
(3 year) favorable outcome, in contrast to patients with
encephalitis due to other infectious causes, 68% of which
had a favorable long-term outcome (Mailles et al. 2012).
The main strength of this study is that case finding was
not limited to national or hospital registers only, but also
on a comprehensive review of virological data. A case defin-
ition was made based on predetermined criteria, which take
clinical, imaging and laboratory parameters into account. It
was not uncommon for patients with a positive PCR for
HSV to have the diagnosis of encephalitis at discharge al-
though the symptoms and clinical course indicated menin-
gitis. The extent of this miscoding in register-based studies
is unclear, but it can have a major effect on the results. In
this study, records from all possible cases were reviewed, in
lieu of the criteria, thus strengthening the case finding
process. In three cases it was possible to obtain old CSF
samples for PCR testing to verify the diagnosis. Moreover,
the study encompasses a whole nation and the duration of
the study period is 25 years. Thus, it involves all verified
cases in a whole country over a quarter of a century.
HSE is a relatively rare disease. The main limitations are
the small population and the retrospective nature of the
study from preexisting case records, which are subject to
bias. Furthermore, retrospective assessment of GCS and
KPS is imprecise as initial data collection and documenta-
tion may have been incomplete. Marked progress in the
diagnosis of HSE took place during the study period, par-
ticularly the introduction of PCR technology. It is possible
that we missed cases occurring prior to that time, but the
incidence was not significantly lower in the early years of
our study and therefore this seems unlikely.
In summary, in spite of the advent of rapid diagnostic
technology and progress in antiviral treatment, HSE re-
mains a very serious disease with a mortality rate of 10%
and approximately three-fourths of the survivors suffer
from serious sequelae. Therefore, further investigations
into its risk factors, epidemiology, pathobiology, as well
as improvements in diagnosis and more effective treat-
ments are of utmost importance.
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